DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
BSX logo

Boston Scientific Corporation Stock Price

NYSE:BSX Community·US$65.2b Market Cap
  • 4 Narratives written by author
  • 1 Comments on narratives written by author
  • 214 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

BSX Share Price Performance

US$44.96
-60.27 (-57.27%)
​
US$62.69
Fair Value
US$44.96
-60.27 (-57.27%)
28.3% undervalued intrinsic discount
US$62.69
Fair Value
Price US$44.96
AnalystConsensusTarget US$62.69
Bill_S US$98.90
AnalystLowTarget US$44.00
Tue, 25 Aug 26
Fair ValueUS$62.69
Share Pricen/a

BSX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$62.69 28.3% undervalued intrinsic discount

Future Growth Plans And Acquisitions Will Drive Broader Market Expansion

1users have liked this narrative
0users have commented on this narrative
77users have followed this narrative
BI
Bill_S's
Fair Value
·
Fair Value US$98.9 54.5% undervalued intrinsic discount

BSX after Penumbra ?

1users have liked this narrative
1users have commented on this narrative
27users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$44 2.2% overvalued intrinsic discount

Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
BSX logo
Boston Scientific
54.5% undervalued intrinsic discount

BSX after Penumbra ?

View narrative
BI
Bill_S
Published 25 Jan
Read Narrative
BSX logo
Boston Scientific
28.3% undervalued intrinsic discount

Future Growth Plans And Acquisitions Will Drive Broader Market Expansion

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 25 Aug
Read Narrative
BSX logo
Boston Scientific
45.7% undervalued intrinsic discount
Updated

Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 8 Sep
Read Narrative
BSX logo
Boston Scientific
2.2% overvalued intrinsic discount

Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 11 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

BI
BSX logo

BSX after Penumbra ?

Fair Value: US$98.9 54.5% undervalued intrinsic discount
27 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
BSX logo

BSX: Shipping Restoration And Reset Expectations Will Set Stage For Recovery

Fair Value: US$82.81 45.7% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
BSX logo

BSX: Long-Term Pipeline Will Offset Watchman And Electrophysiology Headwinds

Fair Value: US$62.69 28.3% undervalued intrinsic discount
77 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with solid track record.

1 Risk
4 Rewards
View Full Analysis

Boston Scientific Corporation Key Details

US$21.0b

Revenue

US$6.5b

Cost of Revenue

US$14.5b

Gross Profit

US$10.9b

Other Expenses

US$3.7b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 28, 2026
2.54
69.19%
17.50%
49.7%
View Full Analysis

About BSX

Founded
1979
Employees
59000
CEO
Michael Mahoney
WebsiteView website
www.bostonscientific.com

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Recent BSX News & Updates

User avatar
Narrative Update • Sep 08

BSX: Shipping Restoration And Reset Expectations Will Set Stage For Recovery

Analysts have trimmed the fair value estimate for Boston Scientific from about $96.91 to $82.81. This reflects a broad reset in price targets after updated guidance for growth, margins and future P/E assumptions, even as recent research points to restored shipping capabilities and ongoing confidence in the company’s longer term product pipeline.
User avatar
Narrative Update • Aug 25

BSX: Long-Term Pipeline Will Offset Watchman And Electrophysiology Headwinds

Analysts have reset expectations for Boston Scientific, cutting the consolidated price target to approximately $62.69 from $72.25 as they factor in reduced long term growth assumptions and a lower future P/E multiple, despite ongoing support for the stock from many firms. Analyst Commentary Street research on Boston Scientific now reflects a reset in expectations, but not a loss of interest in the stock.

Recent updates

No updates

Boston Scientific Corporation Competitors

UNH logo

UnitedHealth Group

Symbol: NYSE:UNH
Market cap: US$359.8b
ABT logo

Abbott Laboratories

Symbol: NYSE:ABT
Market cap: US$182.6b
ISRG logo

Intuitive Surgical

Symbol: NasdaqGS:ISRG
Market cap: US$123.7b
CVS logo

CVS Health

Symbol: NYSE:CVS
Market cap: US$122.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide